Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xyrem sodium oxybate: Phase III

In a 136-patient 4-week Phase III trial, a 9 g Xyrem dose reduced the number of weekly cataplexy

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE